BCIQ Profiles

Company Profile ReportTarget Profile Report

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder
ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study to treat sub-nephrotic patients with orphan kidney disease focal segmental glomerulosclerosis (FSGS), missing

Read the full 473 word article

How to gain access

Continue reading with a
two-week free trial.